Peter Collins is a professor in haematology at the School of Medicine of Cardiff University and an honorary consultant haematologist and director of the Arthur Bloom Haemophilia Centre at the University Hospital of Wales, Cardiff. He trained in haemostasis at The Royal London Hospital, Royal Free Hospital, London and Great Ormond Street Hospita, London.
He is the chair of the UKHCDO Inhibitor working party and serves on the UKHCDO Paediatric working party. He also chairs the UK Haematology Specialty Group as part of the National Institute of Health Research.
Collins PW. Personalized prophylaxis. State of the Art Plenary for The World Federation of Haemophilia Haemophilia. Suppl 4:131-5, 2012. Collins PW, Fischer K, Morfini M, Blanchette VS and Björkman S. On behalf of International Prophylaxis Study Group (IPSG) Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 17:2-10, 2011 Richards M, Williams M, Chalmers E, Liesner R, Collins P, Vidler V, Hanley J; Paediatric Working Party of the United Kingdom Haemophilia Doctors' Organisation. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: Guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol. 149:498-507, 2010 Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Björkman S, Oh M, Spotts G, Schroth P, Fritsch S, Ewenstein BM, Casey K, Fischer K, Blanchette VS, Collins PW. Blood. 119, 612-18, 2011. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic versus on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia a: results from a 13-month crossover study. J Thromb Haemost. 8:83-9, 2010. Collins PW, Björkman S, Fischer K, Blanchette V, Oh M, Schroth P, Fritsch S, Casey K, Spotts G, Ewenstein BM. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe haemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 8:269-75, 2010. S Björkman, VS. Blanchette, K Fischer, M Oh, GD Spotts, P Schroth, S Fritsch, L Patrone, BM Ewenstein and PW Collins. Comparative Factor VIII Pharmacokinetics in Children and Adults: The Influence of Blood Sampling Schedule on Observed Age-Related Differences and Implications for Dose Tailoring. J Thromb and Haemostasis 8:730-736, 2010. PW Collins, VS Blanchette, K Fischer, S Björkman, M Oh, S Fritsch, P Schroth, G Spotts, J Astermark, B Ewenstein. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A. J Thromb Haemost 7:413-420, 2009.